Trial · NCT07385664
Neoadjuvant Chemoimmunotherapy or Chemoradiotherapy in ESCC
NCT07385664, Phase 2, Not yet recruiting, Ji Yongling
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Neoadjuvant Chemoimmunotherapy or Chemoradiotherapy in ESCC. Trials, record NCT07385664. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07385664
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Neoadjuvant Chemoimmunotherapy or Chemoradiotherapy in ESCC
- NCT number
- NCT07385664
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 66 participants, estimated
- Lead sponsor
- Ji Yongling
- Conditions
- Resectable Esophageal Cancer
- Interventions
- Neoadjuvant Chemoimmunotherapy or Concurrent Chemoradiotherapy
- First posted
- 2026-02-04
- Last updated
- 2026-02-04
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | pCR | up to 12 weeks | Based on the FAPI-PET/CT responders after chemoradiotherapy, the pCR rate of the continued neoadjuvant chemoradiotherapy was over 44% |
| Primary | pCR | up to 12 weeks | Patients with a poor FAPI-PET/CT response after chemoradiotherapy were shifted to concurrent chemoradiotherapy, and the pCR rate was no less than 22%. |
| Secondary | MPR | up to 12 weeks | The MPR rate of patients responding to neoadjuvant chemoradiotherapy and FAPI-PET/CT after chemoradiotherapy was based on the MPR rate of patients who continued neoadjuvant chemoradiotherapy, and the MPR rate of patients with a poor FAPI-PET/CT response was converted to concurrent chemoradiotherapy. |
| Secondary | DFS | 1 year | Disease-free survival. Patients responding to neoadjuvant chemoradiotherapy based on FAPI-PET/CT after chemoradiotherapy had a higher 1-year DFS rate than those not responding. |
| Secondary | OS | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months | Overall survival |
| Secondary | FAPI-PET/CT response rate | At the end of Cycle 2(each cycle is 21 days) | The proportion of patients with a change in tumor metabolic activity ≥53% (PET/CT response rate) was evaluated by comparing PFAPI-ET/CT results after chemoradiotherapy as an early predictor of response. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07385664
GET https://conductscience.org/api/trials/v1/NCT07385664/registered